These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 31518227

  • 1. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D, Bortolami M, Scipione L, Pindinello I, Costi R, Di Santo R.
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227
    [Abstract] [Full Text] [Related]

  • 2. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A.
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR.
    J Am Pharm Assoc (2003); 2004 Jul; 44(1):41-51. PubMed ID: 14965152
    [Abstract] [Full Text] [Related]

  • 4. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S, Berrada D, Lembo A.
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [Abstract] [Full Text] [Related]

  • 5. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM, Wagner A, Asia Pacific Gastroenterology Group.
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [Abstract] [Full Text] [Related]

  • 6. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ.
    Cochrane Database Syst Rev; 2007 Oct 17; (4):CD003960. PubMed ID: 17943807
    [Abstract] [Full Text] [Related]

  • 7. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb 17; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 8. Benefit-risk assessment of tegaserod in irritable bowel syndrome.
    Lea R, Whorwell PJ.
    Drug Saf; 2004 Feb 17; 27(4):229-42. PubMed ID: 15003035
    [Abstract] [Full Text] [Related]

  • 9. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec 17; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 10. Tegaserod.
    Scott LJ, Perry CM.
    Drugs; 1999 Sep 17; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
    [Abstract] [Full Text] [Related]

  • 11. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL, Schoenfeld P.
    Drug Saf; 2004 Sep 17; 27(9):619-31. PubMed ID: 15230644
    [Abstract] [Full Text] [Related]

  • 12. In brief: Tegaserod (Zelnorm) returns.
    Med Lett Drugs Ther; 2019 May 06; 61(1571):72. PubMed ID: 31169806
    [No Abstract] [Full Text] [Related]

  • 13. Tegaserod: a new 5-HT4 agonist.
    Lacy BE, Yu S.
    J Clin Gastroenterol; 2002 Jan 06; 34(1):27-33. PubMed ID: 11743242
    [Abstract] [Full Text] [Related]

  • 14. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD.
    Adv Ther; 2009 May 06; 26(5):519-30. PubMed ID: 19444393
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G, Snape WJ, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA.
    Aliment Pharmacol Ther; 2002 Oct 06; 16(10):1701-8. PubMed ID: 12269961
    [Abstract] [Full Text] [Related]

  • 16. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW, Clark WK, Moore DJ, Whorwell PJ.
    Cochrane Database Syst Rev; 2004 Oct 06; (1):CD003960. PubMed ID: 14974049
    [Abstract] [Full Text] [Related]

  • 17. Tegaserod: What's Old Is New Again.
    Sayuk GS, Tack J.
    Clin Gastroenterol Hepatol; 2022 Oct 06; 20(10):2175-2184.e19. PubMed ID: 35123085
    [Abstract] [Full Text] [Related]

  • 18. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S.
    Clin Pharmacokinet; 2002 Oct 06; 41(13):1021-42. PubMed ID: 12403641
    [Abstract] [Full Text] [Related]

  • 19. Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials.
    Shah ED, Lacy BE, Chey WD, Chang L, Brenner DM.
    Am J Gastroenterol; 2021 Aug 01; 116(8):1601-1611. PubMed ID: 34047303
    [Abstract] [Full Text] [Related]

  • 20. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE, Camilleri M, Szarka LA, McKinzie S, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Neurogastroenterol Motil; 2007 Oct 01; 19(10):821-30. PubMed ID: 17539894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.